Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S.K. Mok, Yi-Long Lung Cancer Wu, Iveta Kudaba et al. · The Lancet · 2019

Cited by 3,303 works. doi:10.1016/s0140-6736(18)32409-7

Authors

References